Luis Diaz, co-founder of PGDx, said the new funding will allow the company to “go out and sell” the cancer diagnostics tech it has been working on for a decade.
Image: Baltimore’s Personal Genome Diagnostics (PGDx) has raised about $214 million in funding to date. CARLEY MILLIGAN
Here’s a look at how Johns Hopkins’ COVID-19 website was created and how it grew visits to more than 38 million in seven months.
Image: https://www.healthcarefinancenews.com
University System of Maryland (USM) asked members of its community to get creative with approaches to educating the public on COVID-19 safety ahead of vaccination.
Among the top submissions: a puppet show, an action film parody and, because this is Maryland, a crab.
USM, which oversees a dozen public higher education campuses in the state, issued a Public Health Challenge through its research and innovation task force in December. It called for videos and images “to highlight how USM students, members of the broader university community, and all Marylanders can stay safe and healthy while waiting for a vaccine.”
Image: From “Pandemic Puppet Fatigue.” (Screenshot via University System of Maryland)
The Montgomery County startup is raising new funding — and eyeing an eventual sale of the business.
Image: Sue Carr designed an alternative to the traditional system used for liquid pharmaceuticals. ANDREW BROOKES
GAITHERSBURG, Md., Feb. 11, 2021 (GLOBE NEWSWIRE) — NexImmune, Inc., a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology, today announced the pricing of its upsized initial public offering of 6,471,000 shares of its common stock at a price to the public of $17.00 per share. The gross proceeds to NexImmune from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $110 million.
Maryland is now one of only six states with more than one university entity spending $1 billion or more per year on research, according to the latest rankings from NSF.
Image: A large portion of Johns Hopkins University’s total research and development spending can be attributed to the school’s Applied Physics Laboratory based in Laurel. COURTESY OF JOHNS HOPKINS APPLIED PHYSICS LABORATORY
Baltimore, Md. (Feb. 11, 2020) – The University System of Maryland (USM) COVID Research & Innovation Task Force today announced the six winning teams for its Public Health Challenge. Undertaken with the generous support of several local organizations, the Task Force in mid-December invited members of the USM community to take part in this multimedia challenge, seeking creative ways to highlight how USM students, members of the broader university community, and all Marylanders can stay safe and healthy while waiting for a vaccine.
GENEVA (Reuters) – The World Health Organization (WHO) on Monday listed AstraZeneca and Oxford University’s COVID-19 vaccine for emergency use, widening access to the relatively inexpensive shot in the developing world.
“We now have all the pieces in place for the rapid distribution of vaccines. But we still need to scale up production,” Tedros Adhanom Ghebreyesus, WHO Director-General, told a news briefing.
Image: FILE PHOTO: A vial of AstraZeneca coronavirus disease (COVID-19) vaccine is pictured at St. Mary’s Hospital, in Phoenix Park in Dublin, Ireland, February 14, 2021. REUTERS/Clodagh Kilcoyne
GAITHERSBURG, Md., Feb. 15, 2021 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, and SK Bioscience, a vaccine business subsidiary of SK Group, today announced an expanded collaboration and license agreement. In addition to the already existing manufacturing arrangement, SK Bioscience has obtained a license to manufacture and commercialize NVX-CoV2373, Novavax’ COVID-19 vaccine, for sale to the Korean government. SK Bioscience will add significant production capacity under this new agreement. Novavax recently reported positive interim efficacy results for the vaccine candidate in an ongoing Phase 3 clinical trial in the United Kingdom and is also currently conducting a Phase 3 trial in the U.S. and Mexico.
Artificial intelligence is often depicted in popular movies and TV dramas as technology that is determined to take over the world. Just a few weeks ago, a new series on Fox premiered, highlighting “a rogue AI with the ability to constantly improve itself that may spell doom for humankind.”
